Education and Training
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: CTP-543
Eligibility
Inclusion Criteria:
- Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial
Exclusion Criteria:
- Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical
treatment to the scalp, significant trauma to the scalp, or untreated actinic
keratosis
- Females who are nursing, pregnant, or planning to become pregnant while in the study,
and for 30 days after last dose of study medication
- Donation of blood at any point throughout the study and for 30 days after last dose of
study medication
Ages Eligible for Study
18 Years - 65 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting